Last reviewed · How we verify
FLAMSA
At a glance
| Generic name | FLAMSA |
|---|---|
| Sponsor | Hannover Medical School |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (PHASE1, PHASE2)
- Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML (PHASE3)
- ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLAMSA CI brief — competitive landscape report
- FLAMSA updates RSS · CI watch RSS
- Hannover Medical School portfolio CI